ClinicalTrials.gg
Not yet recruitingNCT07951125Updated Nov 20, 2026

Tranexamic Acid for Recovery After Modified Radical Mastoidectomy in Patients With Chronic Suppurative Otitis Media

A Phase 4 interventional study of Tranexamic Acid (TXA) and Normal Saline (NS) in Tranexamic Acid and Chronic Suppurative Otitis Media, sponsored by Peking University People's Hospital. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Peking University People's Hospital · Phase 4, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main objective of this project is to conduct a multicentre, prospective, randomised, controlled clinical trial to evaluate the clinical value of tranexamic acid in patients undergoing mastoidectomy. The study population consists of patients with chronic suppurative otitis media scheduled to undergo mastoidectomy. They will be randomised in a 1:1 ratio to either the pre-operative intravenous tranexamic acid group or the saline control group; both groups will undergo treatment in accordance with standardised anaesthesia and surgical protocols. The main research components include:

  1. Evaluation of the dry ear rate: The primary outcome measure was to compare the difference in dry ear rates between the two groups one month post-operatively, in order to verify the effect of tranexamic acid on improving the dry ear rate following mastoidectomy. The assessment of the dry ear rate was carried out by an ENT specialist unaware of the study group allocation via clinical otoscopic examination; a dry ear was defined as the absence of discharge in the ear canal and complete epithelialisation of the mastoid surgical site. The assessment time point for the primary outcome measure was one month post-operatively.
  2. Postoperative hearing assessment: This will be assessed based on the improvement in hearing at 3 months postoperatively compared with preoperative levels.
  3. Safety assessment: The safety assessment will primarily include common adverse reactions associated with the use of tranexamic acid (e.g. nausea, vomiting, dizziness) and serious adverse events (e.g. venous thromboembolism, myocardial infarction, epileptic seizures). These will be comprehensively evaluated in conjunction with clinical signs and laboratory tests to ensure the safety and feasibility of the intervention.

Through this study, the project aims to determine whether tranexamic acid can effectively reduce the incidence of dry ear in the early postoperative period following mastoidectomy, and to provide evidence-based support for its clinical implementation.

02

Conditions studied

  • Tranexamic Acid
  • Chronic Suppurative Otitis Media

Browse trials for

Keywords

  • Tranexamic acid
  • radical mastectomy
  • rate of dry ear
  • fibrinolysin
03

In context

Otitis Media

244 studies on the registry are indexed under Otitis Media; 32 are open to participants now.

This study's planned enrollment of 202 is above the median of 165 across 174 interventional studies indexed under Otitis Media.

Browse Otitis Media studies →

Lead sponsor

Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years, regardless of sex
  • (ASA) physical status I-II
  • Patients diagnosed with chronic suppurative otitis media (CSOM) who have had an inadequate response to conservative medical treatment
  • Patients scheduled to undergo microscopic open (canal wall-down) radical mastoidectomy
  • Patients who provide written

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to tranexamic acid (TXA)
  • Severe hepatic or renal disease (hepatic or renal decompensation); thromboembolic diseases, including deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction; a history of epilepsy, including seizures induced by any cause; or coagulation disorders (any of the following coagulation parameters- [APTT], prothrombin time [PT], fibrinogen [FIB], or D-dimer [D-D]-exceeding 1.5 times the )
  • Use of anticoagulant or antiplatelet medications within 2 weeks before surgery, including aspirin, clopidogrel, warfarin, or other such medications
  • Color blindness, pregnancy, or breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
202 participants (estimated)

Study arms

  • Placebo comparator
    Normal Saline (NS) Group

    An equivalent volume of normal saline will be administered intravenously 10 minutes before skin incision.

    Drug: Normal Saline (NS)

  • Experimental
    Tranexamic Acid (TXA) Group

    Tranexamic acid 15 mg/kg will be administered intravenously 10 minutes before skin incision.

    Drug: Tranexamic Acid (TXA)

Interventions

  • DrugTranexamic AcidStudies of Tranexamic AcidTranexamic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tranexamic acid 15 mg/kg will be administered intravenously 10 minutes before skin incision.

  • DrugNormal Saline (NS)

    An equivalent volume of normal saline will be administered intravenously 10 minutes before skin incision.

06

What researchers measure

Primary outcomes

  1. Dry ear rate

    A dry ear is defined as no exudate in the external auditory canal or mastoid cavity and complete epithelialization of the surgical cavity. Dry ear status will be assessed by an otolaryngologist using otoendoscopy.

    Time frame: 1 month (±1 week) after surgery

Secondary outcomes

  1. Hearing improvement

    Pure-tone audiometry will be used to assess hearing thresholds at 0.5, 1, 2, and 4 kHz. Air-conduction (AC), bone-conduction (BC), and air-bone gap (ABG) thresholds will be recorded at each frequency.

    Time frame: 3 months after surgery (±2 weeks)

Other outcomes

  1. Safety and tolerability

    Adverse events will be assessed at postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks), including common adverse events such as nausea, vomiting, and dizziness, as well as serious adverse events such as arterial or venous thromboembolism, myocardial infarction, and seizures. These assessments will be used to evaluate the safety of preoperative intravenous administration of tranexamic acid in patients undergoing modified radical mastoidectomy.

    Time frame: At postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks)

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers due to patient privacy and confidentiality considerations, as well as institutional data protection requirements. Only aggregated study results may be made publicly available through scientific publications.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 20, 2026
StartEst.
Nov 25, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951125
Collaborators
Beijing Municipal Health Commission
Responsible party
Haiyan An, MD (Chief Physician, Peking University People's Hospital) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Haiyan An, MD,PhD
Contact
anhaiyan76@163.com
+86 135 2155 3036

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion